Better Buy Than Competitors? – Avanos Medical, Inc. (AVNS), STAAR Surgical Company (STAA)

Avanos Medical, Inc. (NYSE:AVNS) is simply too cheap to pass with a price-to-sales ratio of 1.34. The competitors from Industrial Specialties hold an average P/S ratio of 6.7, which offer premium compared with the sector’s 6.22. In the past 7-year record, this ratio went down as low as 0.82 and as high as 31.26. Also, it is down from 0.55 of the total 192 rivals across the globe.

AVNS traded at an unexpectedly high level on 01/07/2019 when the stock experienced a 5.52% gain to a closing price of $42.04. The company saw 443254 shares trade hands over the course of the day. Given that its average daily volume over the 5 days has been 401460 shares a day, this signifies a pretty significant change over the norm.

Avanos Medical, Inc. (AVNS) Analyst Gushes

Analysts are speculating a 61.75% move, based on the high target price ($68) for the shares that is set to reach in the next 12 months. The analysts, on average, are forecasting a $57 price target, but the stock is already up 10.63% from its recent lows. However, the stock is trading at -42.38% versus recent highs ($72.96). Analysts believe that we could see stock price minimum in the $36 range (lowest target price), allowing for another -14.37% drop from its current position. Leading up to this report, we have seen a -9.12% fall in the stock price over the last 30 days and a -34.51% decline over the past 3 months. Overall, the share price is down -6.14% so far this year. Additionally, AVNS had a day price range of $39.96 to $42.775.

Avanos Medical, Inc. (AVNS) Price Potential

Heading into the stock price potential, Avanos Medical, Inc. needs to grow just 42.72% to cross its median price target of $60. In order to determine directional movement, the 50-day and 200-day moving averages for Avanos Medical, Inc. (NYSE:AVNS) are $45.4 and $57.85. Given that liquidity is king in short-term, AVNS is a stock with 50.49 million shares outstanding that normally trades 2.95% of its float. The stock price recently experienced a 5-day loss of -3.04% with 2.08 average true range (ATR). AVNS has a beta of 1.62 and RSI is 38.31.

Investors also need to beware of the STAAR Surgical Company (NASDAQ:STAA) valuations. The stock trades on a P/S of 6.67, which suggests that the shares are attractive compared with peers. The broad Ophthalmic Goods industry has an average P/S ratio of 6.7, which is significantly worse than the sector’s 6.22. In the past 13-year record, this ratio went down as low as 0.34 and as high as 18.68. Also, it is down from 0.79 of the total 192 rivals across the globe.

STAAR Surgical Company (STAA)’s Lead Over its Technicals

STAAR Surgical Company by far traveled 127.87% versus a 1-year low price of $13.6. The share price was last seen 5.34% higher, reaching at $30.99 on Jan. 07, 2019. At recent session, the prices were hovering between $28.2 and $31.64. This company shares are 81.51% off its target price of $56.25 and the current market capitalization stands at $1.45B. The recent change has given its price a -16.74% deficit over SMA 50 and -42.61% deficit over its 52-week high. The stock witnessed -12.51% declines, -29.38% declines and -4.2% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found STAA’s volatility during a week at 7.67% and during a month it has been found around 6.67%.

STAAR Surgical Company (NASDAQ:STAA) Intraday Metrics

STAAR Surgical Company (STAA) exchanged hands at an unexpectedly high level of 706146 shares over the course of the day. Noting its average daily volume at 561100 shares each day over the week, this signifies a pretty significant change over the norm.

STAAR Surgical Company Target Levels

The market experts are predicting a 93.61% rally, based on the high target price ($60) for STAAR Surgical Company shares that is likely to be hit in the 52 weeks. Analysts anticipate that traders could see stock price minimum in the $54 range (lowest target price). If faced, it would be a 74.25% jump from its current position. Overall, the share price is down -2.88% year to date.